Bloom 2017.
Study characteristics | ||
Methods |
Study design: secondary analysis of RCT Country: USA Data collection period: not stated Registry ID: not reported |
|
Participants |
Number of participants: N = 61; Number included in meta‐analysis: N = not clear (somewhere between 48 and 51) Sample characteristics (at baseline): Age (mean): aerobic exercise (AE) group 47.1 years (SD 8.5), health education (HEC) group 47.5 years (SD 10.7); Sex (% male): AE 36.7% (11/30), HEC 32.3% (10/31) Population category: general population; Specific population: adults who smoke and not recently engaged in aerobic exercise Nicotine dependence: FTND AE 5.9 (SD 2.1), HEC 5.6 (SD 1.6); Baseline cigarettes per day: AE 20.3 (SD 9.9), HEC 19.4 (SD 8.1); Motivation to quit: selected by motivation to quit |
|
Interventions |
Behavioural support for smoking cessation: all participants (AE and HEC) received 8 sessions of telephone counselling for smoking cessation Pharmacological support for smoking cessation: all participants received 8 weeks of transdermal nicotine patch (TNP) Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management |
|
Outcomes |
Definition of cessation used: self‐reported 7‐day point prevalence abstinence at follow‐ups Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: expired carbon monoxide (CO; < 10 ppm cut‐off); in 1 instance, by the report of a family member of the participant because the participant was unable to provide CO Definition of people who continued to smoke used: exact definition not reported; ‘continued smoking’, carbon monoxide > 10 ppm Time point(s) at which follow‐up was conducted: 3 months (end of treatment), 6 months, and 12‐month follow‐up after baseline Outcome category: Positive Affect; Psychological Quality of Life (QoL) Outcome measure(s): QoL Enjoyment and Satisfaction Questionnaire – Short Form (Q‐LES‐Q‐SF; well‐being and satisfaction domains) |
|
Funding source | Supported by the National Institute on Drug Abuse (grant number K23 DA019950) awarded to Ana M. Abrantes, PhD | |
Author conflicts of interest | No potential conflict of interest was reported by the authors | |
Notes | Outcome data source: Published data |